Table 1 Demographic, clinicopathologic, and postoperative outcomes of patients with Stage IV melanoma to the small bowel who underwent metastasectomy
Patient ID | Gender | Age at First Small Bowel Resection | Location of Primary Melanoma | BRAF V600E Mutation Status | Time from Melanoma Dx to First SB Resection (years) | Sites of Additional Metastasis | Systemic Therapy Prior to SB Resection | Indication for Small Bowel Resection | Number of Bowel Segments Resected | Pallative or Curative Intent | Adjuvant Therapy | Post-operative Follow-up Duration (months) | Patient Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Male | 69 | Unknown | Wild-type | 0.2 | Lung and pancreas | Nivolumab | Intussusception | 2 | Palliative | Nivolumab | 23.7 | DOD |
2 | Male | 75 | Lower extremity | Wild-type | 25.5 | None | None | GI bleeding | 1 | Curative | Pembrolizumab | 43.2 | DUD |
3 | Male | 83 | Unknown | Wild-type | 1.5 | Stomach, lungs, liver, femur, mesentery | Ipilimumab + Nivolumab | Sub-acute obstruction | 1 | Curative | Nivolumab | 53.8 | AWD |
4 | Male | 60 | Neck | Wild-type | 2.7 | Liver | Ipilimumab + Nivolumab, IL-12 | GI bleeding | 3 | Palliative | PD-1 + PI3K inhibitor trial | 13.6 | DOD |
5 | Female | 35 | Hip | Mutant | 15.2 | Brain and lungs | BRAF/MEK inhibitor, Pembrolizumab, Ipilimumab + Nivolumab | Obstruction | 1 | Palliative | BRAF/MEK inhibitor | 47.5 | AWD |
6 | Male | 74 | Uvea | Wild-type | 18.8 | Brain, liver, pancreas, omentum | Ipilimumab + Nivolumab | Elective debulking | 1 | Palliative | Abexinostat + Pembrolizumab trial | 18.8 | DOD |
7 | Male | 37 | Scalp | Mutant | 1.6 | Peri-auricular, spleen, kidney | BRAF/MEK inhibitor, Pembrolizumab + PV-10 trial, abexinostat + pembrolizumab trial | GI bleeding, obstruction | 4 | Palliative | None | 2.2 | DOD |
8 | Female | 67 | Upper extremity | Mutant | 0.1 | Brain | BRAF/MEK inhibitor, Ipilimumab + Nivolumab | Perforation | 1 | Curative | BRAF/MEK inhibitor | 82.6 | NED |
9 | Male | 55 | Chest | Wild-type | 17.2 | Lungs and peritoneum | None | GI bleeding | 1 | Curative | Ipilimumab, Pembrolizumab | 114.7 | NED |
10 | Male | 58 | Toe | Wild-type | 0.1 | Lung and mesentery | None | Intussusception | 2 | Palliative | Ipilimumab + Nivolumab | 30.1 | AWD |
11 | Male | 67 | Scalp | N/A | 9.5 | Lung | Ipilimumab + Nivolumab | Obstruction, GI bleeding | 4 | Palliative | Chemotherapy | 26.3 | AWD |
12 | Female | 79 | Scalp | Wild-type | 9.4 | Liver, pancreas, lungs | None | Elective debulking | 1 | Curative | Pembrolizumab, Ipilimumab + Nivolumab | 40.2 | AWD |
13 | Male | 61 | Unknown | Mutant | 1.8 | Liver, peritoneum, adrenal glands | BRAF/MEK inhibitor, Ipilimumab + Nivolumab, Verzenio | Elective debulking | 1 | Palliative | BRAF/MEK inhibitor | 30.1 | AWD |
14 | Male | 73 | Right abdomen | Wild-type | 10.2 | Brain | Pembrolizumab, Ipilimumab + Nivolumab, MEK inhibitor | GI bleeding | 4 | Palliative | MEK inhibitor | 8.4 | DOD |
15 | Male | 62 | Right upper back | Mutant | 14.3 | Mesentery | Ipilimumab + Nivolumab | Abdominal pain | 1 | Curative | Nivolumab | 23.1 | NED |